This is an open-label, multicenter study to evaluate the safety, pharmacokinetics, and conspicuity of a weight-based Bludigo® dose (0.05 mL/kg rounded up (if necessary) to a minimum of 0.5 mL and not to exceed 2.5 mL) when used as an aid in the determination of ureteral patency in pediatric patients.
The study will enroll approximately 18 pediatric patients from approximately 2-3 study centers in the United States.
Patients scheduled for urological or gynecological surgical procedures who are \< 17 years will be screened for participation.
A minimum of 6 patients will be enrolled in each of the following three age groups: birth to \<6-years old, 6 to \< 12 years old, 12 to \< 17 years old.
Screening will occur within 30 days before study drug administration (Day of Surgery).
After signing the informed consent, review of inclusion and exclusion criteria will be performed. The collection of medical history and concomitant medications, the completion of a physical examination including vital signs measurement, ECG, and the collection of baseline laboratory testing (samples must be collected within 14 days of day 1) will be completed during the screening period.
On the Day of Surgery (Day 1) patients will be evaluated for eligibility for treatment.
To evaluate the efficacy outcomes, each patient will be injected with a weight-based dose of Bludigo® (0.05 mL/kg rounded up (if necessary) to a minimum of 0.5 mL) the maximum dose to be injected is not to exceed 2.5 mL. The ureteral orifices / urine jet will be observed, and a video will be recorded for 10 minutes. The time that will be captured on video is from the time of Bludigo® injection to 10 minutes post injection. If both ureters cannot be visualized simultaneously, then alternating 15-30 second images of each ureter or ureteral orifice will be obtained. The surgeon should note the time blue color is visualized in each ureter jet stream.
Blood samples for PK analysis Urine samples will be collected at 0-30 minutes and 30 minutes- 2 hours post Bludigo® injection.
All treated patients will have a follow-up visit 14 (± 3) days after the procedure. A final telephone call to assess adverse events (AEs) will occur at Day 30 (±2 days).
Safety assessments will include monitoring of vital signs, AEs and laboratory testing post the procedure.
None
None
Single group
Indigotindisulfonate sodium 0.8% injection
DrugExperimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
Responders to Bludigo®
Urine jet conspicuity scores based on the 5-point conspicuity score utilized in study PVP-19IC01 in adults. The 5-point scale is defined as: 1. No jet observed 2. Weak jet, little color contrast 3. Color contrast or significant jet flow 4. Strong jet flow with good color contrast 5. Strong jet flow with striking contrast in color
Time to visualization
Time to visualization of blue color at each ureteral orifice following administration of Bludigo®.
Pharmacokinetics parameters
Amount of Bludigo® excreted in urine.
Area under the curve
Area under the curve
Maximum plasma concentration (C max)
Maximum plasma concentration (C max)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
